DMII

+ Watchlist + Portfolio

Drugs Made In America Acquisition II Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.12
52-Week Range: $9.86 – $10.20
Market Cap: $645.92M
P/E (TTM): 34.97
EPS (TTM): 0.29
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.53
Debt/Equity: —
Total Debt: $450.00K
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $645.38M

DMII Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Selling, General & Admin	$488.38K
Operating Expenses	$1.30M
Operating Income	-$1.30M
EBITDA	-$1.30M
Pretax Income	$4.19M
Net Income	$4.19M
Diluted EPS	0.15
Diluted Shares	27.71M

DMII Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Selling, General & Admin	$59.33K	$38.07K	$155.51K	$235.47K	$132.03K
Operating Expenses	$59.33K	$38.07K	$155.51K	$1.05M	$102.03K
Operating Income	-$59.33K	-$38.07K	-$155.51K	-$1.05M	-$102.03K
EBITDA	-$59.33K	-$38.07K	-$155.51K	-$1.05M	-$102.03K
Pretax Income	-$59.33K	-$38.07K	-$46.16K	$4.33M	$4.34M
Net Income	-$59.33K	-$38.07K	-$46.16K	$4.33M	$4.34M
Diluted EPS	-0.00	—	0.00	—	0.07
Diluted Shares	63.70M	—	29.72M	—	63.70M

DMII Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$6.99K	$4.39K	$315.09K	$223.00	$347.72K
Receivables	—	$2.60K	$566.27K	$0.00	$0.00
Current Assets	$11.57K	$11.57K	$896.36K	$26.04K	$351.76K
Total Assets	$105.09K	$113.39K	$501.01M	$504.96M	$509.73M
Current Liabilities	$281.14K	$327.51K	$677.35K	$300.86K	$666.28K
Total Debt	$250.10K	$297.29K	—	—	$450.00K
Total Liabilities	$281.14K	$327.51K	$18.18M	$17.80M	$18.17M
Retained Earnings	-$211.05K	-$249.12K	-$17.28M	-$17.78M	-$17.82M
Shareholders' Equity	-$176.05K	-$214.12K	$482.83M	$487.16M	$491.56M
Working Capital	-$269.57K	-$315.94K	$219.01K	-$274.83K	-$314.52K
Net Debt	$243.11K	$292.90K	—	—	$102.28K

DMII Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$10.04K	-$2.60K	-$690.73K	-$314.86K	-$102.50K
Free Cash Flow	-$10.04K	-$2.60K	-$690.73K	-$314.86K	-$102.50K
Investing Cash Flow	—	—	—	$0.00	—
Financing Cash Flow	$0.00	$0.00	$501.00M	$0.00	$450.00K
Net Change in Cash	-$10.04K	-$2.60K	$310.69K	-$314.86K	$347.50K

Market Snapshot

About

Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) formed to identify and merge with businesses in the pharmaceutical manufacturing sector. The company focuses on opportunities to bring pharmaceutical production back to the United States. As a blank check company, it has no operations of its own and exists solely to complete a business combination. The SPAC targets companies involved in drug manufacturing, pharmaceutical supply chains, and related healthcare infrastructure.

USD	FY2025
Operating Cash Flow	-$1.02M
Free Cash Flow	-$1.02M
Investing Cash Flow	-$500.00M
Financing Cash Flow	$501.00M
Net Change in Cash	-$16.81K